Transpulmonary Thermodilution Using an Implented Central Venous Access Port
Launched by GUSTAVE ROUSSY, CANCER CAMPUS, GRAND PARIS · Feb 5, 2015
Trial Information
Current as of September 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • presence of port
- • scheduled surgery with perioperative optimization requirement according to the local hemodynamic protocol
- • oral consent of the patient after oral and written information
- Exclusion Criteria:
- • age inferior to 18
- • Contraindication or failure to the insertion of the CVC
- • Contraindication to the use of the port : local or general infection suspected or proved, absence of blood backflow
About Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, located within the Cancer Campus in Grand Paris, is a leading European cancer center renowned for its commitment to innovative cancer research, comprehensive patient care, and advanced treatment methodologies. As a prominent clinical trial sponsor, Gustave Roussy focuses on enhancing therapeutic options and improving outcomes for cancer patients through cutting-edge clinical investigations. The institution fosters collaboration among multidisciplinary teams of experts, leveraging state-of-the-art technologies and a patient-centered approach to drive forward the frontiers of oncology research and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Villejuif, Val De Marne, France
Patients applied
Trial Officials
Alexandre Eghiain, MD
Principal Investigator
Gustave Roussy, Cancer Campus, Grand Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials